Drug Trial Radar · NCT03971409
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
145
Actual
Start
Jul 8, 2019
Primary completion
Jan 31, 2027
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Laura Huppert, MD, BAAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Translational Breast Cancer Research Consortium; Hoosier Cancer Research Network; Array BioPharma; Pfizer; Breast Cancer Research Foundation; Johns Hopkins University; Gilead Sciences
- First posted
- Jun 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
Conditions
- Stage III Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Invasive Breast Carcinoma
- Recurrent Breast Carcinoma
- Triple-Negative Breast Carcinoma
- Unresectable Breast Carcinoma
Interventions
Anti-OX40 Antibody PF-04518600Biological
Given IV
AvelumabDrug
Given IV
BinimetinibDrug
Given PO
UtomilumabBiological
Given IV
Liposomal DoxorubicinDrug
Given IV
Sacituzumab GovitecanDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response Rate (BORR)Time frame: From treatment initiation until disease progression, an estimated average of 1 year
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
O'Neal Comprehensive Cancer Center
Birmingham, Alabama
University of California, San Francisco
San Francisco, California
Georgetown University
Washington D.C., District of Columbia
University of Chicago Medicine Comprehensive Cancer Center
Evergreen Park, Illinois
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Duke Cancer Institute
Durham, North Carolina
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Ingram Cancer Center
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.